Abstract 23P
Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, robust biomarkers precisely predicting treatment response have not yet been discovered. We aimed to evaluate tumor DNA methylation signatures as a potential new biomarker for ICI response.
Methods
Patients with non-small cell lung cancer (NSCLC) receiving ICIs at two independent tertiary care centres were retrospectively identified. DNA methylation profiles of tumor tissue FFPE specimen before initiation of ICI were analysed by Infinium Methylation EPIC microarrays and bioinformatically correlated with radiological response. Responders were defined as patients with complete remission or partial remission at first restaging. Response assessment was performed by board-certified radiologist according to iRECIST v1.1.
Results
In this preliminary analysis, a total of 95 patient samples (median age: 67 years [range: 36-89 years], 53 male, 42 female, 75 adenocarcinoma, 20 squamous cell carcinoma) were included. Supervised clustering according to ICI response revealed three distinct clusters (p<0.001). Cluster 1 included only ICI non-responders (29/29), while the majority of Cluster 3 consisted of responders (11/17). In further analysis according to histological subtype, the 3 clusters were also significantly associated with ICI response in the subgroup of adenocarcinoma as 39/41 (95.1%) in Cluster 1 were non-responders and 10/10 (100%) in Cluster 3 were responders (p<0.001). In squamous cell carcinoma, only 2 methylation clusters were evident. Cluster 1 with only non-responders (14/14) and Cluster 2 with mainly responders (5/6; p<0.001).
Conclusions
Tumor tissue methylation profiling may serve as a promising biomarker to predict ICI treatment response in NSCLC patients.
Legal entity responsible for the study
The authors.
Funding
The financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association is gratefully acknowledged.
Disclosure
J. Furtner: Financial Interests, Personal, Invited Speaker: Seagen, Novartis, Sanova; Financial Interests, Personal, Advisory Board: Servier. A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, CeCaVa, Seagen, Alexion, Servier; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche; Non-Financial Interests, Personal, Leadership Role, Board Member: European Association of Neuro-Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract